Jazz Pharmaceuticals

JAZZ · NASDAQ

$213.76+$5.33 (+2.56%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $208.43

About JAZZ

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Employees: 2,890
Headquarters: DUBLIN, Dublin
Listed: Jan 18, 2012
Sector: Health Care
Industry: Pharmaceuticals
Website: jazzpharma.com

Leadership

Jazz Pharmaceuticals executives
Name	Title	Since	Age
Bruce Cozadd	—	2003	61
Renee Gala	—	2020	53
Philip Johnson	—	—	61
Robert Iannone	—	—	58
Neena Patil	—	—	50
Samantha Pearce	—	—	59
Patricia Carr	—	—	54
Liz Henderson	—	—	53
Thomas Riga	—	—	49
Rick Winningham	—	—	65
Jennifer Cook	—	—	59
Patrick Enright	—	—	63
Laura Hamill	—	—	60
Patrick Kennedy	—	—	56
Ted Love	—	—	66
Heather Mcsharry	—	—	63
Seamus Mulligan	—	2012	64
Anne O'Riordan	—	—	57
Norbert Riedel	—	—	67
Mark Smith	—	—	73
Jeff Macdonald	—	2025	—

Revenue by product and region

Fiscal year ended Dec 31, 2025: $4.27B total revenue

By product

Product sales, net$4.02B94.2%
Royalties and contract revenues$245.74M5.8%

By region

United States$3.83B89.8%
Other$94.87M2.2%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Jazz Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Cardinal Health CAH	Customer	US	0.80
Cigna CI	Customer	US	0.58
Clinigen Group CLIN.L	Customer	GB	0.55
Omnicom OMC	Supplier	US	0.52
PharmaMar PHM.MC	Supplier and customer	ES	0.51
Owens & Minor OMI	Customer	US	0.39
Berkshire Hathaway B BRK.B	Supplier and customer	US	0.24
Springworks Therapeutics SWTX	Supplier and customer	US	0.21
AmerisourceBergen ABC	Customer	US	0.16
McKesson MCK	Customer	US	0.09

Similar companies

Companies in the same industry as Jazz Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.